They didn't present formally and weren't on any of the JPMorgan end-of-day summaries we received each day. We assume they met privately with several firms. It would have been tough for them to present formally with revenue declining so rapidly from 15M to 8.3M to 6M(guess) quarter over quarters. Regenerative medicine revenue wouldn't have been the main talking point, they would be focused on the endo test.
News 
Market Data 
Discover 
AI
